Compare CDLX & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDLX | COCP |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.7M | 21.6M |
| IPO Year | 2018 | 2011 |
| Metric | CDLX | COCP |
|---|---|---|
| Price | $4.12 | $1.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.25 | ★ $6.00 |
| AVG Volume (30 Days) | 44.4K | ★ 57.1K |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.13 | ★ 54.65 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $233,273,000.00 | $12,712,091.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.82 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $0.76 |
| 52 Week High | $6.40 | $2.03 |
| Indicator | CDLX | COCP |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 59.50 |
| Support Level | $3.95 | $0.90 |
| Resistance Level | $4.52 | $1.12 |
| Average True Range (ATR) | 0.32 | 0.07 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 67.82 | 76.59 |
Cardlytics Inc is a commerce media platform that is designed to make commerce smarter and rewarding for everyone. At the core of its commerce media platform is the financial media network that it runs within its partners' digital channels, which includes online and mobile applications (the Cardlytics platform). Additionally, it operates an identity resolution platform that utilizes point-of-sale (POS) data, including product-level purchase data, to enable marketers to perform analytics and targeted loyalty marketing and also measure the impact of their marketing (the Bridg platform). It operates in three segments: the Cardlytics platform in the U.S.; the Cardlytics platform in the U.K.; and the Bridg platform. The majority of the revenue is derived from the Cardlytics platform.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.